Apricus Biosciences, Inc. – Nasdaq: APRI
Shares of Apricus Biosciences shot up on news that Mexico has granted Apricus’ commercialization partner, Ferring Pharmaceuticals, market approval for Vitaros®, an on-demand topical cream indicated for the treatment of patients with erectile dysfunction. Shares, traded on the Nasdaq under ticker symbol APRI, ended Tuesday at $1.51 for the micro-cap drug manufacturer and have been as high as $3.77 in early trading.
This is the twenty-sixth country in which the product has been approved. Richard Pascoe, Chief Executive Officer of Apricus stated in a press release We are very pleased that Ferring has received its second approval for Vitaros in Latin America. Moreover, we look forward to Ferring’s launches of Vitaros in Latin America throughout the year, in addition to the portfolio of countries across the EU they have the rights to as well. Again, congratulations to the Ferring team for their continued commitment to building the Vitaros global brand.”
In 2015 APRI EPS lost $3.83 on sales of $4.8 million. Two firms follow Apricus Biosciences, Inc. One rates APRI shares as a “Buy” the other rates APRI as a “Hold”.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
|Last Price a/o 11:06 AM EST||$ 3.33|
|Market Cap||$12.25 million|
|Shares Outstanding||8.11 million|
|Share Float||6.8 million|
|Short Interest Ratio||0.96|